RxDoctor Payments Data

Kathryn Dempsey, MD

Dermatology · Mobile, ALNPI 1861713273

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $43,500 of the $48,475 with a category attached, or 89.7%. Galderma Laboratories, L.p. accounts for 94.1% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2024 at $25,900 and has fallen 79.3% since, to $5,354 in 2025.

$48,475in general payments, 2019–2025

Across 185 payments — averaging $262.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Galderma Laboratories, L.p.$46K
  • AbbVie$718
  • Sun Pharmaceutical Industries Inc.$383
  • Hill Dermaceuticals, Inc.$284
  • Johnson & Johnson$267
  • Novartis$256
  • plus $974 from 19 others

What the payments were for

  • Speaking & faculty fees$43,50090%
  • Travel & lodging$1,1572%
  • Food & beverage$3,6317%
  • Education$1870%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$48,475 in reported general payments places this provider in the 85th percentile of 168 dermatology providers in Alabama.

See all dermatology providers in Alabama

Medicare billing

Part B allowed, 2024
$75,061
Medicare patients
270
Services billed
1,584

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cosentyx Sensoready (2 Pens)Secukinumab12$86,427
EliquisApixaban12$6,451
Clobetasol Propionate51$1,982
Fluorouracil21$1,767
Acitretin11$1,254
ValacyclovirValacyclovir Hcl43$1,088
Ketoconazole57$979
Fluocinonide22$803
Doxycycline Hyclate39$786
Mupirocin69$654
Metronidazole14$639
Hydroxychloroquine Sulfate29$498
Triamcinolone Acetonide36$307
MethotrexateMethotrexate Sodium17$295
Minoxidil24$204

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$125$6,45112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 168 dermatology providers in Alabama.

Other dermatology in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →